PLL Therapeutics

📢 Our CEO Jean-Pascal Zambaux had an amazing time in Boston at the ALS ONE 7th Annual ALS Symposium! 📋 Jean-Pascal presented the company’s Polypeptide Delivery Platform, which aims to treat ALS at the root cause of disease. 🤝 It was also a good opportunity to meet fellow researchers, partners and investors to discuss the next steps in our development You can learn more about our approach on our website 👇 www.pll-therapeutics.com #ALS #ALSawareness #ALSOne #research #neurodegenerative #diagnostics

📢 We are delighted to share that we have received authorization to start a phase I/II trial in Australia for patients with Amyotrophic Lateral Sclerosis (ALS) ✅ Australia’s Human Research Ethics Committees (HREC) has cleared a first-in-human study of our lead candidate PLL001, which aims to restore the microbiome and stop gut from leaking to treat root cause of ALS, not solely symptoms 💬 “PLL Therapeutics is extremely pleased to have obtained approval from the HREC in Australia to conduct a phase I/II study on ALS patients, a fatal disease with a high unmet need for treatment options. We commend the HREC for facilitating a smooth administrative process in obtaining authorization and accessing resources in conjunction with financial incentives,” said Jean-Pascal Zambaux, co-founder and CEO of PLL Therapeutics. Read the full press release 👇 https://lnkd.in/e9Y4cYSH #biotech #pharma #clinicaltrials #ALS #autoimmune #microbiome #neurodegenerative #diagnostics #innovation 

Meet the PLL Therapeutics Team 👥 Introducing our CEO and co-founder Jean-Pascal Zambaux! 💉 During a career spanning 30+ years in the pharmaceutical and biotech industries, Jean-Pascal has spearheaded many disruptive business models. Prior to founding PLL Therapeutics, Jean-Pascal created Disposable-Lab, a CMO specializing in producing injectable drugs for clinical trials, where he served as CEO between 2008 and 2018, and successfully ran the first pharma company to use a single-use grade A isolator for fill 'n' finish. 📜He also holds a Doctorate in Pharmacy (PharmD) from the Université Paris Cité and the University of Reims Champagne-Ardenne. 📺 Watch the clip below to learn more about PLL Therapeutics' mission from Jean-Pascal! #biotech #pharma #ALS #autoimmune #microbiome #neurodegenerative #diagnostics #innovation

📢 Tomorrow our CEO Jean-Pascal Zambaux will be presenting at the ALS ONE 7th Annual ALS Symposium! During the event, Jean-Pascal will be delivering a presentation on our Polypeptide Delivery Platform, which aims to treat ALS at the root cause of disease. Make sure you catch his presentation tomorrow! Full event details can be found 👇 https://lnkd.in/gi2yUywH 💡 You can learn more about our approach on our website, www.pll-therapeutics.com #ALS #ALSawareness #ALSOne #research #neurodegenerative #diagnostics

🗣️ We are pleased to announce Jean-Pascal Zambaux, CEO of PLL Therapeutics, will be presenting at the ALS ONE 7th Annual ALS Symposium in two weeks! During the fully virtual event, Jean-Pascal will be delivering a presentation titled 'A new diagnostic and therapy paradigm for ALS,' focusing on our Polypeptide Delivery Platform, which aims to treat ALS at the root cause of disease. Make sure you catch his presentation on Tuesday 14 November 2024! Full event details and timings can be found 👇 https://lnkd.in/gi2yUywH 💡 You can learn more about our approach on our website, www.pll-therapeutics.com #ALS #ALSawareness #ALSOne #research #neurodegenerative #diagnostics

🔉 We are thrilled to announce the appointment of Souad K. as Chief Medical Officer of PLL Therapeutics! Souad joins us with over 20 years of experience in European and wider global clinical trial management with a specialty in neurology working in the CNS (Central Nervous System) field with Syneos Health and drug safety at GSK. She will be essential to advancing our lead candidate into phase I studies for ALS 🧠 “I am delighted to join PLL therapeutics as CMO. After working for more than 20 years in clinical trial research, including a focus in neurology, the company’s primary focus on neurodegenerative diseases, its lead candidate for treating ALS and the role of the microbiota-gut-brain axis, are an excellent fit with my experience, expertise and motivation,” said Dr. Kechairi. “PLL Therapeutics combines both treatment and early disease diagnostics. This makes it a one-of-a-kind technology. I am excited to be part of this journey and contribute to the company’s success.” Welcome to the team Soaud! 👏 Read the full press release 👇 https://lnkd.in/efQGBnDv #appointments #CMO #ALS #biotech #diagnostics #autoimmune #microbiome #neurodegenerative

📢 We are excited to announce the launch of our brand-new website! At PLL Therapeutics we are developing a groundbreaking polypeptide delivery platform to treat the root causes of autoimmune and neurodegenerative diseases with the focus on restoring gut permeability. Our first indication is Amyotrophic Lateral Sclerosis (ALS), a fatal motor neuron disease. To date there are few studies on the disease's prevalence, however a report published in Nature Communications in 2016 shows the number of ALS cases across the globe increasing from 222,801 in 2015 to 376,674 in 2040, representing an increase of 69%. Therefore, it is essential for us to find new and innovative therapies to treat the disease and improve the quality of life for patients across the globe. Watch this space for upcoming news! 💻 Visit www.pll-therapeutics.com to learn more about our mission to treat ALS #ALS #biotech #diagnostics #autoimmune, #microbiome #neurodegenerative #innovation, #ALSawareness #gutbrainaxis #immunomodulation #inflammation

📢 We are excited to announce the launch of our brand-new website! At PLL Therapeutics we are developing a groundbreaking polypeptide delivery platform to treat the root causes of autoimmune and neurodegenerative diseases with the focus on restoring gut permeability. Our first indication is Amyotrophic Lateral Sclerosis (ALS), a fatal motor neuron disease. To date there are few studies on the disease's prevalence, however a report published in Nature Communications in 2016 shows the number of ALS cases across the globe increasing from 222,801 in 2015 to 376,674 in 2040, representing an increase of 69%. Therefore, it is essential for us to find new and innovative therapies to treat the disease and improve the quality of life for patients across the globe. Watch this space for upcoming news! 💻 Visit www.pll-therapeutics.com to learn more about our mission to treat ALS #ALS #biotech #diagnostics #autoimmune, #microbiome #neurodegenerative #innovation, #ALSawareness #gutbrainaxis #immunomodulation #inflammation